Night Blindness Treatment Market Report 2024

The night blindness treatment market size has grown strongly in recent years. It will grow from $3.72 billion in 2023 to $3.95 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. The increase observed in the historic period can be attributed to several factors, including a higher prevalence of vitamin A deficiency, an expanding geriatric population susceptible to night vision issues, the growth of healthcare infrastructure, a greater emphasis on nutritional interventions for vision health, and a rising incidence of retinitis pigmentosa.

The night blindness treatment market size is expected to see strong growth in the next few years. It will grow to $5.07 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. The growth projected for the forecast period can be attributed to several factors, the rising adoption of advanced diagnostic technologies, increasing awareness campaigns regarding eye health, a growing demand for personalized medicine, the expansion of eye care clinics and facilities, and advancements in healthcare infrastructure. Major trends anticipated during this period include the adoption of cutting-edge diagnostic technologies, the implementation of personalized treatments, the development of gene therapy and stem cell treatments, the integration of wearable technology for real-time monitoring, and the establishment of multi-disciplinary clinics.

The growing incidence of cataracts is anticipated to drive the expansion of the night blindness treatment market. Cataracts occur when the lens of the eye becomes cloudy, impairing vision. Factors such as increased exposure to ultraviolet (UV) light, smoking, and poor diet contribute to cataract development. Cataracts diminish the eye's ability to discern different shades of light and dark, which is essential for night vision. This reduced contrast sensitivity makes it more challenging to navigate and identify objects in low-light settings. For instance, in July 2023, according to the 2021-23 National UK Eye Care Statistics Survey conducted by the Well-being of Future Generations Act (WFG), a UK-based government agency, there were approximately 16,500 cataract admissions in 2022-23, marking a 23.7% increase from the previous year. Consequently, the rise in cataract cases is fueling growth in the night blindness treatment market.

Key players in the night blindness treatment market are focusing on developing innovative genetic therapies to address the genetic mutations causing the condition, aiming to improve treatment outcomes. Genetic therapies target and repair specific genetic mutations affecting retinal function, potentially restoring vision in those with inherited retinal disorders such as retinitis pigmentosa. For instance, HuidaGene Therapeutics, a US-based clinical-stage biotech firm, introduced HG004 in August 2023. This gene therapy is designed to treat inherited retinal diseases such as Leber's congenital amaurosis and has shown superior results over existing treatments in preclinical studies, aiming to restore retinal function and alleviate night blindness.

In January 2022, Eluminex Biosciences, a Chinese biotechnology company, acquired global development and commercialization rights for Zuretinol (zuretinol acetate) from Retinagenix Holdings LLC for an undisclosed sum. This acquisition enables Eluminex Biosciences to enhance its retinal disease pipeline and develop innovative, non-surgical treatments for vision-threatening conditions such as Leber's congenital amaurosis (LCA) and retinitis pigmentosa (RP), offering potential solutions for the entire retina and both eyes simultaneously. Retinagenix Holdings, a US-based company, is also working on treatments for night blindness.

Major companies operating in the night blindness treatment market are Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Bayer AG, Abbott Laboratories, Novartis AG, Boehringer Ingelheim, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Bausch Health Companies Inc., Eisai Co. Ltd, Cipla Inc., Nature's Way, Spark Therapeutics Inc., Garden of Life, Apellis Pharmaceuticals Inc, Solgar, Acucela Inc., Swanson Health Products, NOW Foods.

North America was the largest region in the night blindness treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the night blindness treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the night blindness treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Night blindness treatment involves interventions designed to address conditions such as vitamin A deficiency and other issues that impair vision in low light conditions. The goal is to improve visual acuity in dim settings and overall visual function by targeting the underlying causes. This treatment aims to enhance the patient's ability to see in low-light environments and at night.

The primary treatments available in the night blindness market include medication, surgery, and other therapies. Night blindness medication focuses on improving vision in low-light conditions by addressing underlying issues such as vitamin A deficiency, retinitis pigmentosa, or other retinal disorders. Diagnosis of night blindness can involve various tests including blood tests, color vision testing, pupil light reflex examination, refraction, retinal exams, and electroretinograms (ERG). Symptoms may include eye pain, vomiting, cloudy vision, halos, light sensitivity, distance vision problems, headaches, and others. The end users of these treatments include clinics, hospitals, and other healthcare facilities.

The night blindness treatment market research report is one of a series of new reports that provides night blindness treatment market statistics, including the night blindness treatment industry global market size, regional shares, competitors with night blindness treatment market share, detailed night blindness treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the night blindness treatment industry. These night blindness treatment market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The night blindness treatment market consists of revenues earned by entities by providing services such as diagnostic services, medical management and consultation, surgical interventions, and genetic counseling and testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The night blindness treatment market also includes sales of night vision goggles, retinal implants and prosthetics, electroretinography (ERG) systems, vitamin A supplements, and intraocular injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.